{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:51:29Z","timestamp":1791341489539,"version":"4.3.1"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":1096,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1124\/dmd.121.000563","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T17:02:33Z","timestamp":1633626153000},"page":"65-75","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Addressing Today\u2019s Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam"],"prefix":"10.1016","volume":"50","author":[{"given":"Stephen","family":"Fowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Cleary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Heinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Husser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidemarie","family":"Kletzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cordula","family":"Stillhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Tuerck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Umehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Poirier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.121.000563_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev.pharmtox.46.120604.141043","article-title":"Human flavin-containing monooxygenases","volume":"46","author":"Cashman","year":"2006","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.121.000563_bib2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1124\/dmd.120.090951","article-title":"Evaluation of erythromycin as a tool to assess CYP3A contribution of low clearance compounds in a long-term hepatocyte culture","volume":"48","author":"Chan","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib3","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1002\/cpt.1216","article-title":"Clinical probes and endogenous biomarkers as substrates for transporter drug-drug interaction evaluation: perspectives from the International Transporter Consortium","volume":"104","author":"Chu","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000563_bib4","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2384","article-title":"Model-based drug-drug interaction extrapolation strategy from adults to children: risdiplam in pediatric patients with spinal muscular atrophy","author":"Cleary","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000563_bib5","first-page":"S5","article-title":"Model-based investigation of CYP3A enzyme inactivation effect of risdiplam in infants, children and adults with spinal muscular atrophy (SMA)","volume":"109","author":"Cleary","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000563_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/cpt.956","article-title":"Model-based assessments of CYP-mediated drug-drug interaction risk of alectinib: physiologically based pharmacokinetic modeling supported clinical development","volume":"104","author":"Cleary","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000563_bib7","first-page":"S5","article-title":"Population and physiologically-based pharmacokinetic modeling of risdiplam in infants, children and adults with spinal muscular atrophy (SMA)","volume":"109","author":"Cleary","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000563_bib8","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.xphs.2018.03.001","article-title":"Improving prediction of metabolic clearance using quantitative extrapolation of results obtained from human hepatic micropatterned cocultures model and by considering the impact of albumin binding","volume":"107","author":"Da-Silva","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000563_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1208\/s12248-020-00482-9","article-title":"In vitro to in vivo extrapolation of metabolic clearance for UGT substrates using short-term suspension and long-term co-cultured human hepatocytes","volume":"22","author":"Docci","year":"2020","journal-title":"AAPS J"},{"key":"10.1124\/dmd.121.000563_bib10","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/2472555219831407","article-title":"Application of new cellular and microphysiological systems to drug metabolism optimization and their positioning respective to in silico tools","volume":"24","author":"Docci","year":"2019","journal-title":"SLAS Discov"},{"key":"10.1124\/dmd.121.000563_bib11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/dmd.121.000356","volume":"49","author":"Eng","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib13","unstructured":"European Medicines Agency (2020) Guideline on the investigation of drug interactions https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed July 2021."},{"key":"10.1124\/dmd.121.000563_bib14","unstructured":"European Medicines Agency (2021) EVRYSDI: Summary of Product Characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/evrysdi-epar-product-information_en.pdf. Accessed July 2021."},{"key":"10.1124\/dmd.121.000563_bib15","doi-asserted-by":"crossref","first-page":"5850","DOI":"10.1038\/s41598-019-42051-x","article-title":"Improved predictions of time-dependent drug-drug interactions by determination of cytosolic drug concentrations","volume":"9","author":"Filppula","year":"2019","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.121.000563_bib16","unstructured":"Food and Drug Administration (2016) Safety Testing of Drug Metabolite: Guidance for Industry https:\/\/www.fda.gov\/media\/72279\/download. Accessed July 2021."},{"key":"10.1124\/dmd.121.000563_bib17","unstructured":"Food and Drug Administration (2018) Drug Development and Drug Interactions https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions. Accessed July 2021."},{"key":"10.1124\/dmd.121.000563_bib18","unstructured":"Food and Drug Administration (2020a) Clinical Drug Interaction Studies \u2014 Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry https:\/\/www.fda.gov\/media\/134581\/download. Accessed July 2021."},{"key":"10.1124\/dmd.121.000563_bib19","unstructured":"Food and Drug Administration (2020b) Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed July 2021."},{"key":"10.1124\/dmd.121.000563_bib20","unstructured":"Food and Drug Administration (2020c) FDA approves oral treatment for spinal muscular atrophy https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-oral-treatment-spinal-muscular-atrophy. Accessed July 2021."},{"key":"10.1124\/dmd.121.000563_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s40495-017-0082-5","article-title":"Progress in prediction and interpretation of clinically relevant metabolic drug-drug interactions: a minireview illustrating recent developments and current opportunities","volume":"3","author":"Fowler","year":"2017","journal-title":"Curr Pharmacol Rep"},{"key":"10.1124\/dmd.121.000563_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.121.000563_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/clpt.2013.74","article-title":"Emerging transporters of clinical importance: an update from the International Transporter Consortium","volume":"94","author":"Hillgren","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000563_bib24","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1124\/dmd.113.056614","article-title":"Systemic exposure to the metabolites of lesogaberan in humans and animals: a case study of metabolites in safety testing","volume":"42","author":"Holmberg","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib25","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1001\/jama.1993.03500120051025","article-title":"Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences","volume":"269","author":"Honig","year":"1993","journal-title":"JAMA"},{"key":"10.1124\/dmd.121.000563_bib26","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3109\/07853890.2011.572905","article-title":"Ritonavir-boosted protease inhibitors in HIV therapy","volume":"43","author":"Hull","year":"2011","journal-title":"Ann Med"},{"key":"10.1124\/dmd.121.000563_bib27","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1124\/dmd.115.066431","article-title":"Low-turnover drug molecules: a current challenge for drug metabolism scientists","volume":"43","author":"Hutzler","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.dmpk.2019.11.009","article-title":"Development of a new Japanese guideline on drug interaction for drug development and appropriate provision of information","volume":"35","author":"Ishiguro","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.121.000563_bib29","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1124\/dmd.117.077396","article-title":"An investigation into the prediction of in vivo clearance for a range of flavin-containing monooxygenase substrates","volume":"45","author":"Jones","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib30","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.121.000563_bib31","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/nbt1361","article-title":"Microscale culture of human liver cells for drug development","volume":"26","author":"Khetani","year":"2008","journal-title":"Nat Biotechnol"},{"key":"10.1124\/dmd.121.000563_bib32","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1208\/s12248-016-0019-7","article-title":"Metabolic profiling of human long-term liver models and hepatic clearance predictions from in vitro data using nonlinear mixed-effects modeling","volume":"19","author":"Kratochwil","year":"2017","journal-title":"AAPS J"},{"key":"10.1124\/dmd.121.000563_bib33","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.pharmthera.2005.01.001","article-title":"Mammalian flavin-containing monooxygenases: structure\/function, genetic polymorphisms and role in drug metabolism","volume":"106","author":"Krueger","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.121.000563_bib34","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1021\/acs.chemrestox.8b00413","article-title":"Highly variable expression of CYP1A1 in human liver and impact on pharmacokinetics of riociguat and granisetron in humans","volume":"32","author":"Lang","year":"2019","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.121.000563_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1046\/j.1365-2125.2000.00265.x","article-title":"In vitro evaluation of potential in vivo probes for human flavin-containing monooxygenase (FMO): metabolism of benzydamine and caffeine by FMO and P450 isoforms","volume":"50","author":"Lang","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000563_bib36","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1124\/dmd.117.077511","article-title":"Metabolism and disposition of a novel selective \u03b17 neuronal acetylcholine receptor agonist ABT-126 in humans: characterization of the major roles for flavin-containing monooxygenases and UDP-Glucuronosyl Transferase 1A4 and 2B10 in catalysis","volume":"46","author":"Liu","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib37","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.121.000563_bib38","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/dmd.111.043158","article-title":"Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions","volume":"40","author":"Mao","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib39","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/s11095-016-1865-9","article-title":"Evaluation of time dependent inhibition assays for marketed oncology drugs: comparison of human hepatocytes and liver microsomes in the presence and absence of human plasma","volume":"33","author":"Mao","year":"2016","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.121.000563_bib40","article-title":"Drug-drug interactions involving renal OCT2\/MATE transporters: clinical risk assessment may require endogenous biomarker-informed approach","author":"Mathialagan","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.121.000563_bib41","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41582-020-00413-4","article-title":"Spinal muscular atrophy - insights and challenges in the treatment era","volume":"16","author":"Mercuri","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1124\/dmd.121.000563_bib42","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/00498254.2019.1643515","article-title":"Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease","volume":"50","author":"Phillips","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.121.000563_bib43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1124\/dmd.117.075036","article-title":"LKY-047: first selective inhibitor of cytochrome P450 2J2","volume":"45","author":"Phuc","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib44","doi-asserted-by":"crossref","first-page":"6501","DOI":"10.1021\/acs.jmedchem.8b00741","article-title":"Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA)","volume":"61","author":"Ratni","year":"2018","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.121.000563_bib45","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000563_bib46","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/dmd.117.079848","article-title":"A decade in the MIST: learnings from investigations of drug metabolites in drug development under the \u201cMetabolites in Safety Testing\u201d regulatory guidance","volume":"46","author":"Schadt","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib47","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1124\/dmd.117.078964","article-title":"Cytochrome P450 2J2: potential role in drug metabolism and cardiotoxicity","volume":"46","author":"Solanki","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1046\/j.1365-2125.2000.00296.x","article-title":"Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity","volume":"50","author":"St\u00f6rmer","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000563_bib49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/bcp.13786","article-title":"A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier","volume":"85","author":"Sturm","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000563_bib50","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/dmd.120.000133","article-title":"Application of the extended clearance classification system (ECCS) in drug discovery and development: selection of appropriate in vitro tools and clearance prediction","volume":"48","author":"Umehara","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib51","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1124\/dmd.118.083295","article-title":"Advances in engineered human liver platforms for drug metabolism studies","volume":"46","author":"Underhill","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.121.000563_bib52","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.121.000563_bib53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pediatrneurol.2020.01.003","article-title":"Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease","volume":"109","author":"Yeo","year":"2020","journal-title":"Pediatr Neurol"},{"key":"10.1124\/dmd.121.000563_bib54","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.xphs.2017.04.045","article-title":"In vitro-in vivo extrapolation of metabolism- and transporter-mediated drug-drug interactions-overview of basic prediction methods","volume":"106","author":"Yoshida","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.121.000563_bib55","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1124\/dmd.117.078691","article-title":"Risk of clinically relevant pharmacokinetic-based drug-drug interactions with drugs approved by the U.S. Food and Drug Administration between 2013 and 2016","volume":"46","author":"Yu","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"Suppl 1","key":"10.1124\/dmd.121.000563_bib56","first-page":"S160","article-title":"Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: an update on the 2018-2019 submissions to the US FDA\u2019s Office of Clinical Pharmacology","volume":"60","author":"Zhang","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.121.000563_bib57","article-title":"Identifying the dominant contribution of human cytochrome P450 2J2 to the metabolism of rivaroxaban, an oral anticoagulant","author":"Zhao","year":"2021","journal-title":"Cardiovasc Drugs Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624007220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624007220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.121.000563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T18:01:25Z","timestamp":1740765685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624007220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0090955624007220"],"URL":"https:\/\/doi.org\/10.1124\/dmd.121.000563","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing Today\u2019s Absorption, Distribution, Metabolism, and Excretion (ADME) Challenges in the Translation of In Vitro ADME Characteristics to Humans: A Case Study of the SMN2 mRNA Splicing Modifier Risdiplam","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.121.000563","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The Author(s)","name":"copyright","label":"Copyright"}]}}